60 Degrees Pharmaceuticals, Inc. (SXTP) Insider Trading Activity

NASDAQ$1.76+0.02 (1.15%)
Market Cap
$1.4M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
361 of 875
Rank in Industry
207 of 501

SXTP Insider Trading Activity

SXTP Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$34,374
4
100
Sells
$0
0
0

Related Transactions

DOW GEOFFREY SPresident and CEO
3
$19,964
0
$0
$19,964
XU CHERYLdirector
1
$14,410
0
$0
$14,410

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.

Insider Activity of 60 Degrees Pharmaceuticals, Inc.

Over the last 12 months, insiders at 60 Degrees Pharmaceuticals, Inc. have bought $34,374 and sold $0 worth of 60 Degrees Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at 60 Degrees Pharmaceuticals, Inc. have bought $80,198 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: DOW GEOFFREY S (President and CEO) — $19,964. XU CHERYL (director) — $14,410.

The last purchase of 9,670 shares for transaction amount of $7,759 was made by DOW GEOFFREY S (President and CEO) on 2025‑12‑15.

List of Insider Buy and Sell Transactions, 60 Degrees Pharmaceuticals, Inc.

2025-12-15PurchaseDOW GEOFFREY SPresident and CEO
9,670
0.2933%
$0.80
$7,759
-27.59%
2025-12-11PurchaseDOW GEOFFREY SPresident and CEO
3,613
0.1177%
$0.92
$3,318
-31.00%
2025-12-10PurchaseDOW GEOFFREY SPresident and CEO
9,350
0.2849%
$0.95
$8,886
-35.11%
2025-06-03PurchaseXU CHERYLdirector
5,000
0.3362%
$2.88
$14,410
-56.36%
2024-12-16PurchaseXU CHERYLdirector
2,000
0.0839%
$1.45
$2,900
-75.50%
2024-12-13PurchaseXU CHERYLdirector
6,000
0.2885%
$1.56
$9,375
-73.62%
2024-12-12PurchaseXU CHERYLdirector
5,000
0.2453%
$1.82
$9,125
-77.33%
2024-12-09PurchaseDOW GEOFFREY SPresident and CEO
35,823
1.437%
$1.27
$45,563
-74.00%
2024-12-06PurchaseDOW GEOFFREY SPresident and CEO
20,579
0.8725%
$1.20
$24,672
-67.13%
2024-12-05PurchaseDOW GEOFFREY SPresident and CEO
17,549
0.7539%
$1.11
$19,520
-68.24%
2024-11-21PurchaseDOW GEOFFREY SPresident and CEO
3,500
0.1312%
$0.91
$3,195
-52.63%
2024-11-20PurchaseDOW GEOFFREY SPresident and CEO
1,000
0.038%
$0.92
$924
-54.46%
2024-11-19PurchaseDOW GEOFFREY SPresident and CEO
2,500
0.0923%
$0.90
$2,248
-53.59%
2024-08-27PurchaseXU CHERYLdirector
5,000
0.349%
$1.70
$8,500
-65.18%
Total: 14
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
DOW GEOFFREY SPresident and CEO
59618
7.3917%
$103,735.3290
<0.0001%
XU CHERYLdirector
15816
1.9609%
$27,519.8450
<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$1,848,072
66
-14.67%
$2.16M
$13,677,131
44
-70.32%
$2.83M
$1,138,733
28
-4.94%
$2.8M
$377,105
24
-39.28%
$1.76M
$8,079,884
14
-43.20%
$703,556.00
$684,058
11
-57.59%
$3.38M
$82,890
11
-16.71%
$1.18M
$389,864
11
12.52%
$3.08M
$18,269
10
-21.15%
$3.33M
60 Degrees Pharmaceuticals, Inc.
(SXTP)
$126,023
10
-66.17%
$1.4M
$90,087
9
20.06%
$3.35M
$7,663,154
8
-48.97%
$1.62M
$70,828
6
-57.96%
$1.17M
$149,778
4
-45.16%
$3.24M
$726,438
4
-72.85%
$1.24M
$157,740
3
153.95%
$2.88M
$1,049,630
1
-74.91%
$824,684.00
$23,454
1
-99.16%
$1,425.00
$37,000
1
79.42%
$2.69M

SXTP Institutional Investors: Active Positions

Increased Positions3+37.5%6,791+63.77%
Decreased Positions2-25%6,350-59.63%
New Positions2New5,891New
Sold Out Positions2Sold Out6,350Sold Out
Total Postitions9+12.5%11,090+4.14%

SXTP Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Drw Securities, Llc$13.000.63%25,211+25,211New2025-09-30
Geode Capital Management, Llc$6.000.31%12,449-67-0.54%2025-09-30
Tower Research Capital Llc (Trc)$2.000.08%3,140+542+20.86%2025-09-30
Ubs Group Ag$1.000.04%1,476+1,462+10,442.86%2025-09-30
Citigroup Inc$00.01%189+189New2025-09-30
Osaic Holdings, Inc.$0<0.01%10000%2025-09-30
Bank Of America Corp /De/$0<0.01%30+17+130.77%2025-09-30
Safe Harbor Fiduciary, Llc$00%0-275Sold Out2025-06-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.